you are here: Home News Pharma Sector

Pharma Sector

Trump’s unpredictable trade moves: 100% tariffs on pharma came just 12 hours after US trade official said none planned
Trump's 50% tariffs threaten Indian goods: Which export sectors could suffer the most | Explained
Indian pharma firms dread tariffs, but US may have the worst side effects
Motilal Oswal predicts robust growth for Indian pharma, picks five stocks to ride the wave
India, Uzbekistan discuss ways to ensure quality, safety in pharma sector
Govt looking to tweak regulatory norms for MedTech, pharma sectors: Niti's VK Paul
Mankind Pharma down as Sikkim floods disrupt operations
US FDA to step up unannounced inspections on Indian pharma plants
Pharma deep dive: Not the time to buy hospitals, bullish on diagnostics, says Incred’s Khemka
Home and away: Indian pharma firms reap the best of both worlds in Q1 FY24
Indian pharma market continues to cool down in July on lag in acute therapies
Here is why Trideep Bhattcharya is bullish on Pharma
Pipeline Check: Here are the blockbuster drugs lined up by Indian drugmakers for US launch
Who's winning the game in the Indian pharma market?
Indian Pharma Market records strong growth for second straight month in May
Pharma market misses estimates as inflation trims volume: Elara Securities
Days of steady US pricing for pharma players to come in FY24, says JM Financial
Pharma Q4 earnings uncover persistent pricing pressure in US generics, says Nomura
Gland Pharma’s prospects after dismal earnings fail to impress investors
Is dual drug filing the right tactic for pharma companies now?
Got Rs 10 lakh to invest? Tata MF’s fund manager picks 3 mutual funds to ride out volatile markets
Brokerage firm Nirmal Bang sees favourable risk-reward in pharma
Pharma industry hails budget’s 'positive thrust on research, innovation'
Budget 2023: FM Sitharaman unveils new programme to promote innovation in pharma
Sun Pharma to get growth boost with addition of Deuroxolitinib to its speciality portfolio: Analysts

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Pharma Sector

Trump’s unpredictable trade moves: 100% tariffs on pharma came just 12 hours after US trade official said none planned

Trump's 50% tariffs threaten Indian goods: Which export sectors could suffer the most | Explained

Indian pharma firms dread tariffs, but US may have the worst side effects

Motilal Oswal predicts robust growth for Indian pharma, picks five stocks to ride the wave

India, Uzbekistan discuss ways to ensure quality, safety in pharma sector

Govt looking to tweak regulatory norms for MedTech, pharma sectors: Niti's VK Paul

Mankind Pharma down as Sikkim floods disrupt operations

US FDA to step up unannounced inspections on Indian pharma plants

Pharma deep dive: Not the time to buy hospitals, bullish on diagnostics, says Incred’s Khemka

Home and away: Indian pharma firms reap the best of both worlds in Q1 FY24

Indian pharma market continues to cool down in July on lag in acute therapies

Here is why Trideep Bhattcharya is bullish on Pharma

Pipeline Check: Here are the blockbuster drugs lined up by Indian drugmakers for US launch

Who's winning the game in the Indian pharma market?

Indian Pharma Market records strong growth for second straight month in May

Pharma market misses estimates as inflation trims volume: Elara Securities

Days of steady US pricing for pharma players to come in FY24, says JM Financial

Pharma Q4 earnings uncover persistent pricing pressure in US generics, says Nomura

Gland Pharma’s prospects after dismal earnings fail to impress investors

Is dual drug filing the right tactic for pharma companies now?

Got Rs 10 lakh to invest? Tata MF’s fund manager picks 3 mutual funds to ride out volatile markets

Brokerage firm Nirmal Bang sees favourable risk-reward in pharma

Pharma industry hails budget’s 'positive thrust on research, innovation'

Budget 2023: FM Sitharaman unveils new programme to promote innovation in pharma

Sun Pharma to get growth boost with addition of Deuroxolitinib to its speciality portfolio: Analysts